Regulator asks state bodies to limit scope of key cancer drug

India's drug regulatory authority has instructed state-level counterparts to mandate manufacturers of Olaparib tablets in 100 mg and 150 mg strengths to cease marketing the cancer medication for patients with advanced ovarian cancer and "gBRCA mutation" (genes associated with tumor suppression), who have undergone three or more rounds of prior chemotherapy treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JcHMwLl
via IFTTT